# Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

> **NCT06031233** · PHASE4 · RECRUITING · sponsor: **Isala** · enrollment: 776 (estimated)

## Conditions studied

- Oncology
- Infusion Reaction

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab
- **DRUG:** Durvalumab
- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **DRUG:** Trastuzumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06031233
- **Lead sponsor:** Isala
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2028-07
- **Final completion:** 2028-12
- **Target enrollment:** 776 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031233, "Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06031233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*